I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 016930-003713US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On <u>W-//-09</u>

TOWNSEND and TOWNSEND and CREW LLP

By: Edward Masmas

Edward Masinas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nielsen et al.

Application No.: 10/823,932

Filed: April 13, 2004

For: COMBINED TUMOR

SUPPRESSOR GENE THERAPY AND

CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS

Examiner: Lacourciere, K.

Art Unit: 1635

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of Supplementary Partial European Search Report EP 98910038.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Nielsen et al.

Application No.: 10/823,932

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Marlin Centle

Nathan S. Cassell Reg. No. 42,396

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

NSC:bjl 60235739 v1

ZFW

6-11-04

Date

				PTO/SB/21 (
PE		Application Number	10/823,932	
TRANSMITTAL FORM		Filing Date	April 13, 200)4
			Nielsen, Loretta	
(to be used for all correspondence after initial t	iling) /		1635	
3	E	Examiner Name	Lacourciere,	, K.
PADEMA Total Number of Pages in This Submission	<u> </u>	Attorney Docket Number	016930-003	713US
	ENCL	OSURES (Check all that a	 ppiy)	
Fee Transmittal Form		Prawing(s)	1 1 1	After Allowance Communication o Group
Fee Attached	Li Li	icensing-related Papers		Appeal Communication to Board of Appeals and Interferences
Amendment/Reply		etition	, L	Appeal Communication to Group Appeal Notice, Brief, Reply Brief)
After Final		etition to Convert to a rovisional Application		Proprietary Information
Affidavits/declaration(s)	PC	rowar of Attorney, Revocation Change of Correspondence Addres		Status Letter
Extension of Time Request		erminal Disclaimer		Other Enclosure(s) (please identify below):
Express Abandonment Request	R	Request for Refund	Return P	Postcard I/08A and /o8B Form
Information Disclosure Statement	│	CD, Number of CD(s)	5 Reference Copies, EP Search Re	
Certified Copy of Priority Document(s)	Remarks	The Commissioner is aut Account 20-1430.	norized to char	rge any additional fees to Depor
Response to Missing Parts/ Incomplete Application				·
Response to Missing Parts under 37 CFR 1.52 or 1.53				
SIGN	ATURE OF	F APPLICANT, ATTORNE	Y, OR AGE	NT
Firm Townsend and Town	send and	Crew LLP		
Individual name Nathan S. Cassell		Reg. I	No. 42,396	·
Signature Maelun	- Ce			
Date 6-10 -	-04			
		ATE OF TRANSMISSION/I	MAII ING	
				" United States Restal Service
'I hereby certify that this correspondence is	Deing tacsinii Invelone addi	le transmitted to the USF (U or o	epositeu with t	the United States Postal Service 1450, Alexandria, VA 22313-1450
the date shown below.	intolopo ada	ressed to. Commissioner for Fak	, 1 .0. 50%	

Edward Mosmas

Signature

Substitute	for form 1449B/PT	0			Complete if Known
11150		DICC	LOSURE	Application Number	10/823,932
INFO	RMATION	אפום	DI ICANT	Filing Date	April 13, 2004
STAT	EMENT B	Y AP		First Named Inventor	Nielsen, Loretta
		ю	שַׁרַ יייטני	Art Unit	1635
(L	ise as many sh	eets as		Examiner Name	Lacourciere, K.
Sheet _.	3	of	TO DADENARIE	Attorney Docket Number	016930-003713US

			U.S. PATENT DO	CUMENTS+	
		Document Number		N	Brace Columns Lines Miles
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		•			

			FO	REIGN PA	TENT DOCUM	ENTS		
Examiner Initials*	Cite No. ¹	Fo	oreign Patent Docume Number ⁴ Kinc	nt i Code ⁶ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Line Where Relevant Passages or Relevan Figures Appear	
	A	wo	> 95/10514	. A1	04-20-1995	Schering Corp.		
	В	WO	95/28948	A1	11-02-1995	Univ. Texas		
		-		-			·	급
•			NON PA	ATENT LIT	ERATURE DO	CUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T²
	C A	HARRIS et al., "Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies" <i>J. Natl. Cancer Inst.</i> (1996) <u>88</u> (20):1442-1455.						_
	D #	NIELSEN et al., "Combination therapy with the Farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in preclinical cancer models" <i>Cancer Research</i> (1999) <u>59</u> :5896-5901.						•
	E '		ıl. "Microtubule-active ancer Research (1995			odazole increase the levels of	of transcriptionally	

60235739 v1

Examiner	,	Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.